HCPCS Level II · Drugs administered other than oral method
J9029Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J9029
J9029 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose.
It was added to HCPCS effective 07/01/2023, and its current record took effect 01/01/2024.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Instill adstiladrin, tx dose
- Date added
- 07/01/2023
- Action effective
- 01/01/2024
- BETOS
- O1D
Related J90xx codes
- J9000Injection, doxorubicin hydrochloride, 10 mg
- J9003Leuprolide injectable (camcevi etm), 1 mg
- J9011Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015Injection, aldesleukin, per single use vial
- J9017Injection, arsenic trioxide, 1 mg
- J9021Injection, asparaginase, recombinant, (rylaze), 0.1 mg
- J9022Injection, atezolizumab, 10 mg
- J9023Injection, avelumab, 10 mg
- J9024Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
- J9025Injection, azacitidine, 1 mg
- J9026Injection, tarlatamab-dlle, 1 mg
- J9027Injection, clofarabine, 1 mg
Common questions about J9029
Is HCPCS J9029 still valid?
- Yes. J9029 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J9029?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.